Conformation-specific inhibitory anti-MMP-7 monoclonal antibody sensitizes pancreatic ductal adenocarcinoma cells to chemotherapeutic cell kill

Mohan, Vishnu, Gaffney, Jean P., Solomonov, Inna, Levin, Maxim, Klepfish, Mordehay, Akbareian, Sophia, Grünwald, Barbara, Dym, Orly, Eisenstein, Miriam, Yu, Kenneth H., Kelsen, David P., Krüger, Achim, Edwards, Dylan R. ORCID: https://orcid.org/0000-0002-3292-2064 and Sagi, Irit (2021) Conformation-specific inhibitory anti-MMP-7 monoclonal antibody sensitizes pancreatic ductal adenocarcinoma cells to chemotherapeutic cell kill. Cancers, 13 (7). ISSN 2072-6694

[thumbnail of Published_Version]
Preview
PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview

Abstract

Matrix metalloproteases (MMPs) undergo post-translational modifications including pro-domain shedding. The activated forms of these enzymes are effective drug targets, but generating potent biological inhibitors against them remains challenging. We report the generation of anti-MMP-7 inhibitory monoclonal antibody (GSM-192), using an alternating immunization strategy with an active site mimicry antigen and the activated enzyme. Our protocol yielded highly selective anti-MMP-7 monoclonal antibody, which specifically inhibits MMP-7′ s enzyme activity with high affinity (IC50 = 132 ± 10 nM). The atomic model of the MMP-7-GSM-192 Fab complex exhibited antibody binding to unique epitopes at the rim of the enzyme active site, sterically preventing entry of substrates into the catalytic cleft. In human PDAC biopsies, tissue staining with GSM-192 showed characteristic spatial distribution of activated MMP-7. Treatment with GSM-192 in vitro induced apoptosis via stabilization of cell surface Fas ligand and retarded cell migration. Co-treatment with GSM-192 and chemotherapeutics, gemcitabine and oxaliplatin elicited a synergistic effect. Our data illustrate the advantage of precisely targeting catalytic MMP-7 mediated disease specific activity.

Item Type: Article
Uncontrolled Keywords: drug synergy,fas ligand,gemcitabine,matrilysin,matrix metalloproteinase-7,monoclonal antibody,oxaliplatin,pancreatic ductal adeno-carcinoma,oncology,cancer research,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2730
Faculty \ School: Faculty of Science > School of Biological Sciences
Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Centres > Norwich Institute for Healthy Aging
Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 16 Apr 2021 23:58
Last Modified: 21 Apr 2023 01:00
URI: https://ueaeprints.uea.ac.uk/id/eprint/79808
DOI: 10.3390/cancers13071679

Actions (login required)

View Item View Item